Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Conference

related documents

• 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.  Conferences
• A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.  Conferences
• A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.  Conferences
• A phase I study of [²²⁵Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.  Conferences
• A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.  Conferences
• A phase II study of durvalumab re-treatment plus /- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A)  Conferences
• A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.  Conferences
• A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid premedication for docetaxel chemotherapy.  Conferences
• A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer.  Conferences
• Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience.  Conferences
• Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).  Conferences
• Ascertaining cancer survivors in Ontario using the Ontario Cancer Registry and administrative data.  Conferences
• Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR plus breast cancer in the TEAM trial.  Conferences
• Association between locoregional failure and NFE2L2/KEAP1/CUL3 pathway mutations in NRG/RTOG 9512: A randomized trial of hyperfractionation vs. conventional fractionation in T2N0 glottic squamous cell carcinoma (SCC).  Conferences
• Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).  Conferences
• Association of socioeconomic status (SES) with use of specialist palliative care (SPC) among people who died with cancer before and during the COVID-19 pandemic.  Conferences
• BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy  Conferences
• CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570)  Conferences
• CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).  Conferences
• CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)-RAINBO BLUE and TAPER  Conferences
• CCTG PR21: A randomized phase II study of [¹⁷⁷lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997)  Conferences
• Can synthetic data accurately mimic oncology clinical trials?  Conferences
• Cancer patient attitudes and preferences towards smoking status assessment.  Conferences
• Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among patients with advanced prostate cancer.  Conferences
• Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).  Conferences
• Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.  Conferences
• CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.  Conferences
• Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial.  Conferences
• Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naive, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.  Conferences
• Clinical outcomes of pancreas cancer patients with peritoneal spread: Results from the chord consortium.  Conferences
• Comparing cervical cancer stage at diagnosis in immigrant women and long-term residents.  Conferences
• Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada.  Conferences
• Cost-effectiveness of nodal observation versus completion lymphadenectomy in patients with melanoma and sentinel lymph node metastases.  Conferences
• Cytoreductive surgery (CRS) and heated intra-peritoneal chemotherapy (HIPEC) in the management of peritoneal carcinomatosis in a community setting.  Conferences
• Demonstrating the value of liquid biopsy for lung cancer in a public health care system.  Conferences
• Detection of bladder cancer relapse after TURBT through urinary tumor DNA analysis: A prospective real-world evidence study  Conferences
• Developing and evaluating new models of care in hematology.  Conferences
• Dissecting outcomes of patients (pts) with < ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.  Conferences
• Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI.  Conferences
• Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.  Conferences
• Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer.  Conferences
• Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.  Conferences
• Education modalities for serious illness communication training: A scoping review on the impact on clinician behavior and patient outcomes  Conferences
• Effect of neoadjuvant immunotherapy and targeted therapies on surgical resection in patients with solid tumors: A systematic review and meta-analysis.  Conferences
• Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial.  Conferences
• Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26.  Conferences
• Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.  Conferences
• Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.  Conferences
• Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach  Conferences
• Evaluating the impact of survivorship models on health system resources and costs.  Conferences
• FRACTION-RCC: Innovative, high-throughput assessment of nivolumab plus ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).  Conferences
• First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).  Conferences
• Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices.  Conferences
• Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.  Conferences
• Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).  Conferences
• Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.  Conferences
• Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) plus /- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).  Conferences
• Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).  Conferences
• KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.  Conferences
• LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T₁N₀ luminal A breast cancer (BC).  Conferences
• Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).  Conferences
• Locoregional recurrence following pathologic complete response in patients with T1-3 N0 breast cancer treated with neoadjuvant chemotherapy, breast conserving surgery and whole breast radiation: Is a trial of omission of radiation warranted?  Conferences
• Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.  Conferences
• Multi-site implementation of patient-reported outcome measures for personalized care and patient activation in symptom management.  Conferences
• Multisystem immune-related adverse events from dual agent immunotherapy use  Conferences
• Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).  Conferences
• Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.  Conferences
• Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.  Conferences
• Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC).  Conferences
• Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203  Conferences
• Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study.  Conferences
• Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.  Conferences
• Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.  Conferences
• Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia.  Conferences
• Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.  Conferences
• Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR).  Conferences
• Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial  Conferences
• Pre-screening test for clinical trials of Autologous γδ T lymphocyte therapy for advanced cancer.  Conferences
• Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A Canadian multicenter analysis from the CHORD Consortium.  Conferences
• Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.  Conferences
• Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).  Conferences
• Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort.  Conferences
• Readmission and emergency department visits in the peri-treatment period for head and neck cancers patients in Ontario.  Conferences
• Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada.  Conferences
• Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)  Conferences
• Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch^mut).  Conferences
• SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.  Conferences
• Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study.  Conferences
• Suggested reclassification strategy applied to intermediate and poor risk nonseminomatous germ cell tumors (NSGCT): A two-institution combined analysis.  Conferences
• The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement.  Conferences
• The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).  Conferences
• The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma  Conferences
• The characterization of IDH1 mutations in Chinese biliary tract cancers.  Conferences
• The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.  Conferences
• The impact of a well breast cancer patient transition model of care on oncologists’ practice.  Conferences
• The impact of primary pancreatic tumor location on clinical outcomes in advanced disease: Results from the chord consortium.  Conferences
• The impact of routine ESAS use on overall survival: Results of a population-based retrospective matched cohort analysis.  Conferences
• The impact of tobacco retail density on overall survival (OS) in lung cancer survivors.  Conferences
• Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors.  Conferences
• Treatment outcomes for newly diagnosed, untreated TP53-mutated acute myeloid leukemia: A systematic review and meta-analysis.  Conferences
• Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.  Conferences
• Ultra-sensitive baseline-informed MRD assay to predict prognosis outcomes in patients with resectable hepatocellular carcinoma.  Conferences
• Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.  Conferences
• Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study  Conferences
• Using cognitive interviews and expert feedback to validate the Australian AYA Distress Thermometer and Problem Checklist for use in Canada.  Conferences
• Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).  Conferences
• Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.  Conferences
• Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?  Conferences
• weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration resistant prostate cancer.  Conferences